Laboratory Co. of America (NYSE:LH) Updates FY 2025 Earnings Guidance

Laboratory Co. of America (NYSE:LH) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 15.600-16.400 for the period, compared to the consensus earnings per share estimate of 15.990. The company issued revenue guidance of $13.9 billion-$14.1 billion, compared to the consensus revenue estimate of $13.8 billion.

Laboratory Co. of America Trading Down 0.4 %

NYSE:LH traded down $1.04 on Friday, reaching $246.70. The stock had a trading volume of 392,838 shares, compared to its average volume of 605,257. Laboratory Co. of America has a 12-month low of $191.97 and a 12-month high of $258.59. The firm’s fifty day moving average is $236.56 and its two-hundred day moving average is $229.47. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The company has a market cap of $20.63 billion, a price-to-earnings ratio of 47.71, a P/E/G ratio of 1.86 and a beta of 1.07.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. Equities analysts expect that Laboratory Co. of America will post 14.51 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is currently 55.71%.

Analyst Ratings Changes

LH has been the subject of a number of research analyst reports. Hsbc Global Res raised shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Barclays increased their target price on shares of Laboratory Co. of America from $249.00 to $271.00 and gave the stock an “equal weight” rating in a research report on Monday. Bank of America increased their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. StockNews.com downgraded shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Piper Sandler increased their target price on shares of Laboratory Co. of America from $235.00 to $240.00 and gave the stock a “neutral” rating in a research report on Monday, October 28th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $264.62.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Glenn A. Eisenberg sold 11,711 shares of Laboratory Co. of America stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $240.43, for a total value of $2,815,675.73. Following the completion of the transaction, the executive vice president now owns 31,289 shares of the company’s stock, valued at $7,522,814.27. The trade was a 27.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the transaction, the director now directly owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. This represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,572 shares of company stock valued at $5,915,209. 0.85% of the stock is currently owned by corporate insiders.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.